Insider Selling: InspireMD (NYSE:NSPR) Insider Sells 7,073 Shares of Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 7,073 shares of InspireMD stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $2.51, for a total value of $17,753.23. Following the completion of the transaction, the insider owned 1,109,733 shares in the company, valued at $2,785,429.83. The trade was a 0.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total value of $23,005.78.

InspireMD Trading Up 3.0%

Shares of NYSE NSPR traded up $0.03 during mid-day trading on Thursday, reaching $1.03. The company had a trading volume of 160,140 shares, compared to its average volume of 182,457. The stock has a market cap of $48.24 million, a PE ratio of -1.37 and a beta of 0.82. The company has a 50-day moving average price of $1.40 and a two-hundred day moving average price of $1.68. InspireMD, Inc. has a 1-year low of $0.97 and a 1-year high of $2.93.

Key InspireMD News

Here are the key news stories impacting InspireMD this week:

• Neutral Sentiment: Shane Thomas Gleason disclosed multiple recent sales of InspireMD shares, including transactions on May 19, May 23, May 27, May 29, May 30, and earlier January/February dates. Each filing says the sales were made to cover tax withholding obligations related to the vesting of equity awards, which makes the activity look more routine than a strategic exit. Article Title
• Neutral Sentiment: A new “Stock Forecast & Price Target” page for InspireMD may be contributing to increased trading interest, but the item itself does not include a specific rating change, earnings update, or business development that would clearly drive the shares. Article Title

Institutional Investors Weigh In On InspireMD

Institutional investors have recently modified their holdings of the stock. Ghisallo Capital Management LLC acquired a new stake in shares of InspireMD during the 3rd quarter valued at $2,221,000. Aberdeen Group plc acquired a new stake in shares of InspireMD in the 3rd quarter valued at $5,979,000. Rosalind Advisors Inc. lifted its stake in shares of InspireMD by 70.6% in the 3rd quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock valued at $9,413,000 after purchasing an additional 1,616,644 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of InspireMD in the 4th quarter valued at $31,000. Finally, XTX Topco Ltd acquired a new stake in shares of InspireMD in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 44.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on NSPR shares. Piper Sandler reissued an “overweight” rating and set a $3.00 target price (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Loop Capital set a $5.00 target price on shares of InspireMD in a research note on Tuesday, February 24th. Lake Street Capital set a $4.00 target price on shares of InspireMD in a research note on Monday, May 4th. Finally, Maxim Group started coverage on shares of InspireMD in a research note on Monday, February 2nd. They set a “buy” rating and a $6.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.